quest diagnost post solid fve unchang
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim
price data
rate updat
currenc amount express
valuat growth profit
methodolog valu compani
posit lead provid
independ diagnost test build network
patient servic center across countri
think quest size cost advantag allow benefit
sever secular trend includ prolifer diagnost
test greater clinic relianc diagnost test
person therapi increas demand clinic
test drive higher volum diagnost lab across countri
quest primari nation competitor labcorp domin
independ diagnost test landscap thank vast nation
network laboratori two firm creat barrier
entri gener substanti cost advantag region
hospit lab industri seen steadi consolid
compani acquir smaller competitor recent
quest focus establish presenc hospital-bas
lab either oper consult basi
compani also seek expand footprint higher-margin
gene-bas patholog test diagnost test becom
increasingli complex reliant train specialist hospit
often outsourc esoter test independ lab quest
acquisit ameripath athena celera boost
firm portfolio esoter test
despit quest formid size attract cost structur
firm histor trail peer labcorp oper effici
diagnost busi nonetheless quest still gener
econom profit underscor strength moat
current manag team spent past four year focus
on-going integr acquisit play catch-up
oper front streamlin organ greater
effici final begin see tangibl hint result
turnaround effort profit growth
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
lead independ provid diagnost test
inform servic compani gener
revenu clinic test anatom patholog esoter test
substanc abus test nation network patient servic
center firm also run diagnost solut segment provid
clinic trial test risk assess servic inform technolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
quest diagnost post solid fve
post solid fourth-quart result
gener met expect leav fair
valu estim unchang even though quest face
major exogen challeng includ pama-l
medicar cut firm done good job navig
on-going price pressur made new
opportun remain confid quest narrow moat
expect signific cost advantag serv
firm well even smaller independ hospital-bas
lab fall substanti financi pressur due pama
grow intens test usag could help quest absorb
lower medicar reimburs revenu
quest hit top-lin project nearli
nose servic rose wed estim
off-set sell market expens
came substanti lower wed anticip organ
quarterli volum growth soft price per
requisit remain robust
importantli pleas see modest price
pressur fourth quarterless basi point
though price declin may acceler medicar
cut play next coupl quarter moreov
trend toward higher-tech test play
quest favor though manag offer explan
trend specul might relat
adopt checklist best practic
provid use effort address quality-of-car
object associ afford act also
expect quest profession lab servic segment
maintain acceler growth hospital-bas
lab feel urgenc fight stay viabl
medicar cut institut consid small
hospital-bas lab outsourc
test volum there upsid quest captur
valuat growth profit sep
modestli lower fair valu estim
per share adjust impact propos
consid first batch price revis appli
test conduct often
date think adjust greater impact
taper base
case assum quest medicar revenu
subject maximum reduct follow
year
consist equiti research assumpt
corpor tax reform continu incorpor
 corpor rate fall chang
corpor tax rate outsiz effect quest
busi virtual firm revenu deriv
domest firm highli leverag
requir heavi capit invest result
lower project effect tax rate
continu expect gradual volum gain healthcar
util resum volum final stabil late
seen gradual steadi growth sinc
macroeconom condit eas healthcar util
gradual recov think compani focu
esoter test pay segment return
mid-single-digit growth
pharmaceut biotech compani aim
person target therapi expect steadi
stream new biomark discoveri greater applic
molecular diagnost across clinic spectrum
bode well quest anticip growth higher-margin
complex test partial off-set price pressur
routin test howev recogn cut
reimburs anatom patholog remain soft spot
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
bear-cas scenario project weaker util
maximum cut medicar clinic lab fee schedul
longer term translat averag annual
growth anatom patholog growth remain
flat in-sourc continu slowli esoter test
revenu growth exceed firm
benefit oper leverag product mix turn
unfavor headwind would translat
oper margin hover averag also
assum corpor tax rate remain
put fair valu estim per share
quest enjoy narrow moat part duopoli
domin independ refer lab market compar
hospital-bas lab smaller region player
quest typic offer signific cost advantag thank
scale volum exampl test hospit lab
typic cost time averag test
quest advantag becom evid
throughput increas translat high oper
leverag addit firm nationwid footprint
extens network patient servic center
in-physician offic servic would difficult replic
scratch quest advantag cost structur
nation coverag also appeal payer
structur reimburs polici funnel patient
larg independ lab payer typic would rather
negoti largest refer lab includ quest
provid best geograph coverag insur
instead cobbl togeth market-by-market
coverag multipl smaller region lab final
quest scale reach make attract partner
research invent variou diagnost test
distribut channel sell test
hold quest moat trend stabl larg
quest believ cut substanti
enough spur specialist practic outsourc path
lab though could see behavior
overal pressur contain cost filter individu
practic overal think oper margin includ
depreci grow mid- high-teen
base averag volatil cash flow
underli diagnost test busi think medium
uncertainti appropri quest
best-cas scenario assum esoter test
prove stronger expect see averag annual
revenu growth next five year mix shift drive
oper margin also assum routin
test volum price gain outperform adjust
medicar clinic lab fee schedul favor
expect cut corpor tax rate take
place case rais fair valu estim
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
higher-pr rival like hospit constitut primari
competit keep eye impend
expir long-term exclus contract
labcorp set end late leav
open unit field propos long-term
contract near term base signific
cost reduct unit demand last time
enter negoti surpris
competit limit largest
independ lab enjoy deepest cost advantag
final think opportun industri
horizon move away
volume-bas
reimburs could posit independ
diagnost lab healthcar reform shepherd
reimburs valu instead volum think
opportun diagnost firm captur
valu histor elud industri industri
estim diagnost test account less total
healthcar spend influenc approxim
treatment decis industri demonstr
valu think quest competitor could captur
larger portion healthcar pie
weak util rel well key trend
diagnost lab market add favor condit
independ lab specif new experi among
payer push financi risk onto provid made
doctor hospit price-sensit come
lab test dynam put end
encroach hospital-affili lab quest
labcorp busi hospital-bas lab
gain market share independ thank
gener reimburs polici favor hospit
set concurr move toward hospit
purchas physician practic direct test
hospit lab trend hospit pull back
invest lab reli independ lab
outsourc test also mean primari
advantag largest independ refer lab -- lower
cost -- grow relev practition payer
includ autom
integr autom
quest one key challeng maintain moat
continu lower cost structur quest key lever
endeavor
technolog consolid lab facil
meantim expect quest continu snap smaller
competitor
oper think firm like moder
acquisit larger target offer higher-margin
complex test capabl work integr
sizabl purchas alreadi made recent quest
pursu opportun manag hospital-bas
lab type arrang
econom attract wholesal purchas
non-inpati
non-outpati yet clear much influenc
competit quest labcorp remain ration
point think irrat price unlik long
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oadvanc technolog person medicin
increas number complex esoter
gene-bas test avail patient test
gener carri higher profit margin quest
oquest activ seek hospital-outreach
program roll acquisit offer
attract econom quest
organ patient record lab test inform
databas doctor use
like refer patient quest facil
oquest
oper
ineffici current manag team
yet fulli turnaround oper
oquest previou strateg foray indian
market anim health disappoint
ultim kept manag focus
improv oper quest mainstay routin
esoter test segment
oon anecdot basi consist heard
complaint patient poor servic quest
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
even roll-up strategi quest maintain manag
balanc sheet activ contribut rise debt
leverag earli sinc firm deleverag
repay debt expand profit
march total debt stood billion time ebitda
beyond quest recent de-lever matur schedul
look manag near term exist cash
million march avail credit facil
senior note due within next five year million
due million due sinc estim
quest abl gener roughli million
annual free cash flow averag next five year
think problem meet
oblig especi take measur approach
quest assert pursu variou on-sit
oper arrang hospital-bas lab firm
may abl realiz mani oper effici
roll hospit outreach program could
pose difficulti quest enhanc profit think
grow relianc electron medic record could
also hinder volum growth duplic test fall
health system reli proprietari electron medic
record keep independ lab favor intern
hospital-bas lab lower price larg insur would
lead smaller profit quest labcorp quest
consist eke oper effici
firm could see profit buckl pressur
payer new medicar reimburs rate
clinic lab fee schedul propos
still question exact impact combin
cut increas could quest guidelin
left hospital-bas lab equat calcul
market reimburs rate test mean
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
reimburs rate aggreg influenc
outsiz way quest labcorp -- two lowest-cost
produc first batch reimburs adjust
address one quintil test commonli
conduct well gone longest
without adjust actual impact depend
test mix volum quest nevertheless expect
overal medicar clf reimburs fall time
place heavier financi burden hospital-bas
lab smaller independ lab think
ultim translat higher volum quest
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
fiduciari manag inc milwauke
capit research manag compani
share
fund
share
fund
rate quest stewardship standard follow
manag turnov think quest becom
focus capital-alloc decis recent
introduc number improv make govern
shareholder-friendli applaud compani
design jenn britel non-execut chairman
board also like inclus tim ring ceo cr
bard board long admir ring team
disciplin prudent deploy capit
quest adopt annual elect director
instead stagger three-year term previous
place quest shift away bonu target tie
earn per share toward metric includ revenu
growth return invest capit realiz cost
effici believ compani past use stock
option compens excess
particularli hope dynam chang
current manag -- ceo steve rusckowski award
nearli million stock option award first
year quest anoth million year sinc
final think would like see manag
director take larger equiti stake firm execut
offic director less stock
past particularli impress
firm record capit alloc mainli
cohes strategi guid invest
howev rusckowski leadership quest
focus acquir stand-alon lab special
esoter diagnost hospit outreach program
well forg flexibl allianc hospital-bas
lab includ arrang quest manag
hospit lab think move reinforc quest
moat broaden firm menu test increas
test volum ultim contribut firm
attract cost structur howev appear
manag display innov vision
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
seen rival labcorp anticip emerg
like genom scienc value-bas
reimburs could significantli reshap
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
final rule medicar price fail shift fve
follow final rule chang medicar clinic
lab fee schedul driven protect access
medicar act hold steadi fair valu
estim see chang
firm narrow econom moat although impact cut
slightli less wed origin anticip
remain cut beyond larg consist
project small adjust made
immateri intrins valu point
main factor account fair valu estim
roughli higher share current trade
chalk expect chang come tax reform
effort led republican consist morningstar
equiti research guidelin corpor tax reform
continu assum corpor rate fall
chang corpor tax rate outsiz
effect quest busi virtual firm
revenu deriv domest firm highli
leverag requir heavi capit invest
fee-schedul chang believ like
new reimburs rate roll januari even
though price heavili skew largest
lowest-cost competitorsquest labcorp sonic
recogn industri object center
medicar medicaid servic defin lab
collect market-bas test price problemat
hospital-bas lab still account half
whole diagnost lab market howev convinc
current administr particularli
sympathet interest revisit issu persuad
revis approach collect market data
long-term endeavor perspect
quest diagnost deliv solid quarter pama
follow solid perform third quarter quest
diagnost track meet full-year project
leav fair valu estim unchang
narrow-moat compani continu see decent increas
volum revenu per requisit driven mainli test
mix densiti requisit despit hurrican
damp volum growth estim basi point
propos reimburs cut medicar clinic
lab fee schedul come pama remain larg cloud
refer lab market bake
adjust anticip reduct time
frame magnitud cut consider
larger industri expect think
possibl moder quest
labcorp industri associ seek rais concern
legisl
cut could small materi effect
quest there doubt smaller independ lab
hospital-bas lab bear brunt impact
continu think lowest-cost produc best
posit absorb near- mid-term reimburs
pressur also benefit longer run
smaller competitor shift away busi
close shop sell busi outsourc test
although difficult peg exactli divers
test volum take place increment benefit quest
labcorp anticip see lab sale
closur time frame nonetheless on-going
acquisit quest -- includ recent announc
purchas shiel medic cleveland clinic
heartlab -- lead us believ pama-rel cut
migrat value-bas reimburs
acceler trend
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
mix assum half quest medicar revenu
affect maximum cut reimburs
follow anoth medicar revenu
fifth test code revis come year
appli less common test
less impact quest medicar revenu
point think chanc delay
implement low technic
obstacl stand way roll new
payment howev think chanc final
reimburs rate could revis upward especi
hospit vocal concern payment
adjust would hit smaller lab chin
midterm expect either funnel
test volum larg independ like quest close
door altogeth
test dialysi patient
anticip see steadi flow hospit
healthcar provid decid get diagnost test
shiel medic great exampl own freseniu
medic shiel conduct in-hous intens
reimburs dialysi provid partial link
well provid keep patient within certain test
rang relat kidney function shiel rel
small portion freseniuss busi strateg
standpoint ancillari main focu dialysi
expens diagnost test includ bundl
lower cost diagnost test outsourc
quest labcorp instead run lower-volum
fair valu estim quest sep
re-examin impact propos reimburs
adjust medicar clinic lab fee schedul
weve modestli lower fair valu estim quest
per share although propos
reimburs cut larger wed anticip
quest attract cost structur mean firm
rel strong posit handl cut continu
think quest narrow econom moat intact
longer term small lab buckl price
pressur volum come quest
base propos payment first batch test
code project medicar cut slice basi
point origin annual growth assumpt
greatest impact first two year due
adjust test commonli conduct
date price much
depend assumpt quest exposur
first test code revis compani
disclos littl inform test volum
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
